By: ICN Bureau
Last updated : January 12, 2026 4:38 pm
Dr. Bagul has a proven track record of leading the research and operation teams in bridging the gap between complex synthetic chemistry and commercial business viability
Shivtek Spechemi Industries Ltd, a leading specialty chemicals manufacturer and flagship company of the Shiva Group of Industries, has announced the appointment of Dr. Trusar D. Bagul as an Independent Director to its Board.
Holding a PhD in Organic Chemistry from the National Chemical Laboratory (NCL), Pune, Dr. Bagul brings a rare combination of profound academic research and industrial expertise to the board. The strategic appointment is part of Shivtek’s continued focus on strengthening governance, deepening technical oversight, and supporting its long-term growth and innovation roadmap.
With close to three decades of experience in chemistry research and management spanning across drug discovery, pharmaceutical, fine chemical, and specialty chemical segments, Dr. Bagul brings deep scientific acumen combined with strong business and operational insight.
A prolific researcher with multiple international scientific publications, US and Indian patents to his credit, Dr. Bagul has a proven track record of leading the research and operation teams in bridging the gap between complex synthetic chemistry and commercial business viability. His expertise in "High Value - Low Volume" projects and cost-effective chemical development is expected to be a cornerstone for Shivtek’s upcoming R&D initiatives.
As an Independent Director, Dr. Bagul will be responsible for helping Shivtek’s research and development team. Dr. Bagul’s appointment is designed to provide the board with deep technical oversight as the company navigates the complex, technology-driven expansions.
Dr. Bagul is an accomplished organic and medicinal chemist with extensive experience across drug discovery, fine chemicals, pharmaceutical intermediates, and chemistry services.